Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P830063/S030

Prismaflex TPE2000 Set

Vantive US Healthcare, LLC · Decision date Mar 13, 2026

FDA DECISIONP830063/S030

What did the FDA approve?

FDA records P830063/S030 as a supplement to PMA P830063, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Mar 13, 2026.

FDA approval order statement

Extend Prismaflex TPE2000 Set EO sterilization to STERLAB new supplier (scope of the P830063/A013 notification) for the Chambers #11 and #14, increase the sterilization load by changing palletization configuration from 4 layers of boxes to 5 layers of boxes per pallet at STERLAB, and qualify a new EO supplier STERISERVICES, for the Chamber ATC011
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Gastroenterology, Urology
Decision date
Mar 13, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P830063/S030
Regulatory pathway
PMA supplement
Product code
MDP
Decision code
APPR
Decision date
Mar 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Separator for therapeutic purposes, membrane automated blood cell/plasma.

Product code
MDP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P830063/S030 received

    Application receipt date recorded by FDA.

  2. P830063/S031 · Related supplement

    Gambro Prismaflex TPE 2000 Set

  3. P830063/S030 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P830063. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P830063

Product / regulatory recordCompanyPathwayDecision dateSource
Vantive US Healthcare, LLCPMA supplementDec 23, 2025FDA
Vantive US Healthcare, LLCPMA supplementJul 15, 2026FDA

Explore the linked device profile

Other records with product code MDP

Product / regulatory recordCompanyPathwayDecision dateSource
Asahi Kasei Medical Co., Ltd.PMA supplementApr 9, 2026FDA
Asahi Kasei Medical Co., Ltd.PMA supplementSep 30, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vantive US Healthcare, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
510 Lake Cook Rd., Deerfield, IL, 60015

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records